Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)
A legfontosabb adatok
- Ki végzi
- University of Colorado, Denver
- Hol
- Aurora (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 2. fázis
- Résztvevők
- 50 fő vett részt
- Kezdés
- 2024. jan. 11.
- Befejezés
- 2025. nov. 15.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Semaglutide 3 MG [Rybelsus]
- Semaglutide 7 MG [Rybelsus]
- Placebo
- A regiszteradat frissítve
- 2025. december 26.
Ki vehet részt
- Életkor
- 21 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Age 21 or older
- Meets Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria for current AUD of at least moderate severity, as assessed by the Mini International Neuropsychiatric Interview (MINI)
- Seeking pharmacological treatment for AUD and wants to stop or cut down on drinking
- Has a body mass index (BMI) of at least 25 kg/m2
- Able to read and understand questionnaires and informed consent
- Lives within 50 miles of the study site; Please contact clinical site for additional inclusion criteria
Ki nem vehet részt
- Urine drug screen at screening positive for any substance except cannabis
- Current use of other psychotropic medications except antidepressants (for which dose must be stable for at least the past 2 months)
- Current or past-month use of weight control medications
- Any prior use of semaglutide or other GLP-1 agonists
- (If participating in MRI sessions) Contraindications to MRI scanning, ferrous metal in the body including intracranial, intraorbital, or intraspinal metal, pacemakers, cochlear implants, other non-MRI-compatible devices, or other devices that could compromise the quality of the MRI images such as a permanent top retainer or braces
- Current DSM-5 diagnosis of any other substance use disorder of moderate or greater severity, except for Nicotine Use Disorder, as assessed by MINI
- Current DSM-5 bipolar disorder, major depressive episode, or panic disorder, as assessed by MINI
- Current or lifetime eating disorder (anorexia, bulimia, or binge eating disorder) or psychotic disorder, as assessed by MINI
- History of severe alcohol withdrawal (e.g., seizure, delirium tremens), as evidenced by self- report and assessment with Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar)
- Personal history of gastrointestinal disease (e.g., gastroparesis) or pancreatitis
- Personal or family history of medullary thyroid carcinoma and/or multiple endocrine neoplasia syndrome type 2
- Uncontrolled hypertension (systolic BP >160 mmHg or diastolic >100 mmHg)
- Current or lifetime Type 1 or Type 2 diabetes diagnosis, or HbA1c >6.5%
- Current or lifetime kidney disease or creatinine clearance <80 mL/min for participants <=55 years of age (<65 mL/min for those >55)
- Current or past hepatocellular disease, as indicated by verbal report or elevations of serum amylase, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times the upper limit of the normal range at screening
- Current suicidal ideation or homicidal ideation
- Current or past-month use of AUD pharmacotherapy, including (e.g., oral naltrexone, acamprosate, or disulfiram) or current or past 60-day use of injectable naltrexone
- Current psychotherapy in which the primary focus is AUD. Attendance at Alcoholics Anonymous (AA) meetings is not exclusionary
- Current or past-month use of metformin for any indication
- Biological females of childbearing potential who are pregnant (by plasma HCG), nursing, or who are not using a reliable form of contraception
- Lack of a stable living situation
- (If participating in MRI sessions) Severe claustrophobia or morbid obesity that preclude placement in the MRI scanner
Helyszínek itt: Egyesült Államok
- University of Colorado Anschutz Medical CampusAurora, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study is a randomized controlled trial of oral semaglutide among treatment-seeking individuals with AUD. The investigators will randomly assign 50 participants to receive semaglutide (titrated to 7 milligrams (mg) per day) or matched placebo for 8 weeks. The primary aims are to assess the safety and tolerability of semaglutide in this population and to evaluate its effects, relative to placebo, on alcohol cue-elicited craving and alcohol consumption.
A vizsgálat 2 csoportja
- PlaceboPlacebo, összehasonlításként
Participants in this Arm will take a medically inert placebo. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the capsule orally each morning.
- Semaglutide 3 milligrams and 7 milligramsMár használt kezelés, összehasonlításként
Participants in this Arm will study medication for a total of 8 weeks - on semaglutide 3 milligrams per day for 4 weeks, then 7 milligrams per day for 4 weeks. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the capsule orally each morning.
Kezelés: Semaglutide 3 MG [Rybelsus] és Semaglutide 7 MG [Rybelsus]
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Randomized, Controlled Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)
- A regiszteradat frissítve
- 2025. december 26.